Skip to main content
    P

    Profound Medical Corp (PROF)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $7.34
    -0.08 (-1.08%)

    Market Cap: $271.77M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Profound Medical Corp (PROF) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Profound Medical reported EPS of -$0.21, below the -$0.19 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    40%(16/40)
    Avg Surprise
    -0.16%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.19
    Range-$0.21 - -$0.19
    5 analysts
    Revenue Consensus
    $8.85M
    Range$7.64M - $11.03M
    5 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.22
    Range-$0.24 - -$0.18
    3 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.21-5.7%
    60d ago-$0.21-5.7%
    30d ago-$0.21-5.7%
    7d ago-$0.21-5.7%
    Current-$0.22
    Revenue Consensus
    $11.88M
    Range$11.61M - $12.27M
    3 analysts

    Next Report

    PROF's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    PROF Earnings Call

    The latest PROF earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, PROF beat 16, missed 22 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $9.83M, up 85.8% from $5.29M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.21-$0.19-$0.22 - -$0.16-10.53%MissN/A42 up, 0 downNov 5, 2026$9.83M
    Jun 30, 2026$0.26-$0.22-$0.29 - -$0.19+218.18%BeatN/A42 up, 2 downAug 6, 2026$2.48M
    Mar 31, 2026-$0.19-$0.25-$0.31 - -$0.23+24.00%BeatN/A51 up, 1 downMay 7, 2026$5.34M
    Dec 31, 2025-$0.27-$0.30-$0.30 - -$0.24+10.60%BeatN/A31 up, 0 downMar 5, 2026$5.98M
    Sep 30, 2025-$0.26-$0.38-$0.44 - -$0.32+31.58%BeatN/A52 up, 0 downNov 13, 2025$5.29M
    Jun 30, 2025-$0.52-$0.40-$0.47 - -$0.34-30.00%MissN/A40 up, 1 downAug 14, 2025$2.21M
    Mar 31, 2025-$0.36-$0.28-$0.31 - -$0.26-28.57%MissN/A40 up, 2 downMay 8, 2025$2.62M
    Dec 31, 2024-$0.20-$0.32-$0.39 - -$0.26+37.98%BeatN/A41 up, 1 downMar 6, 2025$4.18M
    Sep 30, 2024-$0.38-$0.30-$0.35 - -$0.26-26.67%MissN/A40 up, 0 downNov 7, 2024$2.83M
    Jun 30, 2024-$0.28-$0.28-$0.34 - -$0.250.00%In lineN/A40 up, 0 downAug 8, 2024$2.23M
    Mar 31, 2024-$0.26-$0.31-$0.37 - -$0.26+16.13%BeatN/A40 up, 0 downMay 9, 2024$1.44M
    Dec 31, 2023-$0.42-$0.32-$0.40 - -$0.23-31.25%MissN/A70 up, 0 downMar 7, 2024$2.66M
    Sep 30, 2023-$0.26-$0.32-$0.40 - -$0.31+18.75%BeatN/A50 up, 0 downNov 2, 2023$1.73M
    Jun 30, 2023-$0.35-$0.34-$0.38 - -$0.28-2.94%MissN/A60 up, 0 downAug 9, 2023$1.60M
    Mar 31, 2023-$0.32-$0.34-$0.40 - -$0.25+5.88%BeatN/A50 up, 0 downMay 10, 2023$1.86M
    Dec 31, 2022-$0.46-$0.36-$0.40 - -$0.31-27.78%MissN/A50 up, 0 downMar 7, 2023$1.70M
    Sep 30, 2022-$0.24-$0.38-$0.49 - -$0.23+36.84%BeatN/A60 up, 0 downNov 3, 2022$2.81M
    Jun 30, 2022-$0.28-$0.39-$0.45 - -$0.36+28.21%BeatN/A70 up, 1 downAug 4, 2022$2.01M
    Mar 31, 2022-$0.40-$0.43-$0.55 - -$0.37+6.98%BeatN/A50 up, 0 downMay 9, 2022$1.71M
    Dec 31, 2021-$0.49-$0.37-$0.46 - -$0.24-32.43%MissN/A50 up, 0 downMar 3, 2022$1.26M
    Sep 30, 2021-$0.29-$0.30-$0.36 - -$0.14+3.33%BeatN/A3N/ANov 4, 2021$3.21M
    Jun 30, 2021-$0.35-$0.30N/A-16.67%MissN/AN/AN/AAug 4, 2021$2.60M
    Mar 31, 2021-$0.37-$0.29N/A-27.59%MissN/AN/AN/AMay 12, 2021$893599
    Dec 31, 2020-$0.49-$0.43N/A-13.95%MissN/AN/AN/AMar 2, 2021$3.66M
    Sep 30, 2020-$0.33-$0.24N/A-37.50%MissN/AN/AN/ANov 5, 2020$2.24M
    Jun 30, 2020-$0.35-$0.21N/A-66.67%MissN/AN/AN/AAug 6, 2020$1.03M
    Mar 31, 2020-$0.18-$0.26N/A+30.77%BeatN/AN/AN/AMay 7, 2020$1.16M
    Dec 31, 2019-$0.32-$0.49N/A+34.80%BeatN/AN/AN/AMar 3, 2020$2.17M
    Sep 30, 2019-$0.43-$0.38N/A-13.16%MissN/AN/AN/ANov 7, 2019$682224
    Jun 30, 2019-$0.38-$0.33N/A-15.15%MissN/AN/AN/AAug 14, 2019$437316
    Mar 31, 2019-$0.22-$0.33N/A+33.33%BeatN/AN/AN/AMay 6, 2019$1.11M
    Dec 31, 2018-$0.50-$0.45N/A-11.11%MissN/AN/AN/AMar 7, 2019$1.22M
    Sep 30, 2018-$0.38-$0.34N/A-11.76%MissN/AN/AN/ANov 8, 2018$235032
    Jun 30, 2018-$0.38-$0.29N/A-31.03%MissN/AN/AN/AAug 14, 2018$162213
    Mar 31, 2018-$0.47-$0.31N/A-51.61%MissN/AN/AN/AMay 10, 2018$291414
    Dec 31, 2017-$0.60-$0.50N/A-20.00%MissN/AN/AN/AMar 26, 2018$1.89M
    Sep 30, 2017-$0.70-$0.56N/A-25.00%MissN/AN/AN/ANov 7, 2017$1.47M
    Jun 30, 2017-$0.08-$0.07N/A-14.29%MissN/AN/AN/AAug 23, 2017$957139
    Mar 31, 2017-$0.51-$0.52N/A+1.92%BeatN/AN/AN/AMay 9, 2017$591517
    Dec 31, 2016-$0.07-$0.07N/A0.00%In lineN/AN/AN/AMar 6, 2017N/A
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.41, after -$1.12 the year before. It was -$1.62 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.41N/A
    Dec 31, 2024-$1.12N/A
    Dec 31, 2023-$1.35N/A
    Dec 31, 2022-$1.38N/A
    Dec 31, 2021-$1.50N/A
    Dec 31, 2020-$1.35N/A
    Dec 31, 2019-$1.35N/A
    Dec 31, 2018-$1.73N/A
    Dec 31, 2017-$1.89N/A
    Dec 31, 2016-$1.62N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,400 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,39811
    2026Q2Jun 30, 20265,77610
    2025Q4Dec 31, 20256,91211
    2025Q3Sep 30, 20255,1829
    2025Q2Jun 30, 20256,62711
    2025Q1Mar 31, 20255,79710
    2024Q4Dec 31, 20244,5488
    2024Q3Sep 30, 20245,6289

    2026Q3 Earnings Call

    Opening remarks

    Stephen Kilmer Investor Relations Thank you, operator, and good afternoon, everyone. Welcome to Profound Medical's Third Quarter 2026 Conference Call. Let me start by pointing out that this conference call will include forward-looking statements within the meaning of applicable securities laws in the United States and Canada. All forward-looking statements are based on Profound's current beliefs, assumptions and expectations, and relate to, among other things, current or future financial performance and position, our revenue and gross margin outlook, commercialization activities, customer utilization, product development, leadership succession and expectations regarding the efficacy of our technologies. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied. No forward-looking statement can be guaranteed. Listeners are cautioned not to place undue reliance on these statements, which speak only as of today. Please review the risk factors described in our filings with the U.S. and Canadian securities regulators. Profound undertakes no obligation to publicly update or revise forward-looking statements, except as required by law. Joining us today are Dr. Arun Menawat, Chief Executive Officer and Chairman; Matthew Sobczyk, our Chief Financial Officer; Tom Tamberrino, our Chief Commercial Officer; Mathieu Burtnyk, our Chief Technology Officer; and Richard Fabian, our current President and incoming CEO. We have lots to discuss today. Matthew will begin with our financial results, followed by Rich on operational priorities and Tom on commercial progress. Arun will then provide a strategic update before we open the call to questions. Just a heads-up in that regard: Arun is just getting over a bad cold, so his voice might break up a bit here and there. With that, I'll turn the call over to Matthew.

    Matthew Sobczyk CFO Good afternoon, everyone. On behalf of the management team and everyone at Profound, thank you for your continued interest and support. Before turning the call over to Rich for an operational update, I'll briefly review our third quarter 2026 financial results. For the three months ended September 30, 2026, Profound recorded total revenue of $9.8 million, up 86% from the third quarter of 2025. Revenue comprised $4.1 million of recurring noncapital revenue from single-use devices and service associated with extended warranties, and $5.7 million of capital equipment sales. Gross margin was 78% compared with 74% in the prior-year quarter, reflecting a favorable product mix and continued strong price discipline. Operating expenses were $15.5 million, an increase of 21% year over year. The increase primarily reflected increased headcount, increased commission expense driven by our revenue growth, travel expenditures and higher consulting expenditures due to spending on R&D initiatives to reduce product costs and improve efficiencies.

    Frequently Asked Questions About PROF

    Did PROF beat earnings estimates last quarter?

    No. Profound Medical reported EPS of -$0.21 for the quarter ended Sep 30, 2026, below the -$0.19 estimate by 10.53%.

    What EPS do analysts expect from PROF next quarter?

    The consensus EPS estimate for Profound Medical for the quarter ending Dec 31, 2026 is -$0.19 from 5 analysts, with estimates from -$0.21 to -$0.19.

    How often does PROF beat earnings estimates?

    Profound Medical beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +31.66%.